Heterologous prime-boost immunization with CoronaVac and Convidecia
Jingxin Li(Beijing Tongren Hospital), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Shipo Wu(Academy of Military Medical Sciences), Lairun Jin(Southeast University), Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Tao Zhu, Jiahong Zhu, Xue Wang(Hunan Institute of Science and Technology), Pengfei Jin(Jiangsu Provincial Center for Disease Control and Prevention), Yin Chen(Southern Medical University), Junqiang Li(China Pharmaceutical University), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Wei Chen(Beijing Fengtai Hospital), Xiaoyu Xu, Xuewen Wang(Shenzhen University Health Science Center), Jingxuan Wan(CanSino (China)), Lihua Hou(Academy of Military Medical Sciences), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Zhizhou Song
Cited by 33
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204